Tagged with R

MNCs Lloyd D. Balajadia, Executive Director of Lloyd Laboratories talks about the advantages and disadvantages of the recent spike in generic medicine within the Philippine market, why despite a contract manufacturer being good for Lloyd Laboratories, it would be but bad for the job market and business opportunities in the Philippines,…

diabetes Christine Marie D. Rosal, Country Manager of Novo Nordisk Pharmaceuticals (Philippines) gives a startling image of the current state of diabetes in the Philippines, the major reasons behind the soaring rates of diabetes and what the government along with companies such as Novo Nordisk can do to prevent a worsening…

Generics Executive Director, Teodoro B. Padilla, and Reiner W. Gloor, Adviser of Pharmaceutical & Healthcare Association of the Philippines (PHAP) argue that certain government initiatives, like discounted prices for senior citizens and students without financing them, put a perilous amount of pressure on the sector, and the necessity of raising awareness…

R&D Dr. Olsson Birgersson, Medical Director of Roche Sweden argues the importance of developing clinical research within Sweden, why the Swedish healthcare system is no longer the forerunner in Europe that it once was, and Roche’s intentions of further strengthening personalized healthcare products while adapting to the needs of their costumers.…

UAE The two founders and managing partners of Genpharm talk about the market dynamics of the UAE, and the gaps in the market that the company was able to fill with its portfolio offering.    Karim, can you speak to us about the birth of Genpharm, and more broadly about your…

Basic Research “If you look at the cuts in the public sector, the science budget has been relatively lightly touched. This sends a signal at a very high level that science, the knowledge economy, and the smart training of people are very important for our economic recovery,” says Mark Ferguson, Director General,…

Life Sciences Michael Chiang, the Executive President of Panion & BF Biotech speaks about the incredible growth of the company over the past year, what has contributed to this success and where Panion & BF will be in the next five years. Please provide us with a brief insight into the history…

Life Sciences James Wang, Country Managing Partner of Ernst & Young Taiwan explains why Taiwan’s DIG (Diversify-Innovative-Globalize) strategy is crucial for the growth of Taiwan’s economy over the next decade, why biotech will be the leading industry in this new strategy and that less reliance on China will be necessary for an…

UAE Dr Ali Al Sayed, Director of the Pharmaceutical Services Department at the Dubai Health Authority and Chairman of DUPHAT Conference, speaks about the current endeavor of the Government to make the healthcare system in Dubai more accessible and cost-effective for everyone, how competition is healthy for the industry, and where…

APL Care With over 6,000 inhabited islands forming the country of Indonesia, making sure that drugs are where they are needed, when they are needed, is a major challenge. How is this challenge managed today, and what will happen once the government introduces universal healthcare in January 2014? A manager that won…

Choice Pharma Full service CRO Choice Pharma moved its operations from Europe to Asia in 2008, and since then the company has thrived. The managing director and business director for the company discuss the merits of Taiwan for CROs, and how the environment is better today in Asia than in Europe for…

Chief Scientist of Quebec Rémi Quirion, Chief Scientist of Québec, discusses how Canada needs to promote itself more aggressively, and highlights ways in which Canada can use industry-academia partnerships to its advantage, as well as international collaboration. What areas of research and science are being targeted the most for investment in Quebec? In terms…